Lorenz Räber, MD PhD(@RaberLorenz) 's Twitter Profileg
Lorenz Räber, MD PhD

@RaberLorenz

EO Professor of Interventional Cardiology | enthusiastic father of 3 | politics | wine | cooking | fishing | tweets my own

ID:733355807002243072

calendar_today19-05-2016 17:57:04

855 Tweets

1,3K Followers

478 Following

Thrombosis & Haemostasis, TH,TH Open(@TH_Journal) 's Twitter Profile Photo

🫀 Does Alirocumab affect function in patients with ? ⤵️

📌 Among pts. receiving DAPT in the PACMAN-AMI Trial, had no significant effect on platelet reactivity

In TH current issue 👉 thieme-connect.de/products/ejour…

Lorenz Räber, MD PhD

account_circle
PCRonline 🫀(@PCRonline) 's Twitter Profile Photo

Pretreatment with P2Y12 inhibitors in - insights from the Bern-PCI Registry

This study sought to compare outcomes 📈📉 between patients presenting with STEMI before & after the recent ESC guidelines for the management of ACS recommendation against pre-treatment with…

Pretreatment with P2Y12 inhibitors in #STEMI - insights from the Bern-PCI Registry This study sought to compare outcomes 📈📉 between patients presenting with STEMI before & after the recent ESC guidelines for the management of ACS recommendation against pre-treatment with…
account_circle
Lorenz Räber, MD PhD(@RaberLorenz) 's Twitter Profile Photo

In the Bern PCI registry, we evaluated the impact of the recent downgrade of P2Y12i preloading in STEMI (ESC Guidelines) as we stopped preloading in 2018. No preloading was not associated with increased hazards in ischemic outcomes 30days. Read jacc.org/doi/10.1016/j.… European Society of Cardiology

account_circle
JAHA(@JAHA_AHA) 's Twitter Profile Photo

sbaer Lorenz Räber, MD PhD and colleagues show that in ACS patients with multi-vessel disease undergoing planned staged PCI, non-culprit quantitative flow ratio did not identify patients benefiting from earlier intervention. ahajrnls.org/3HeeJTe

@BaerSarah_ @RaberLorenz and colleagues show that in ACS patients with multi-vessel disease undergoing planned staged PCI, non-culprit quantitative flow ratio did not identify patients benefiting from earlier intervention. #AHAJournals ahajrnls.org/3HeeJTe
account_circle
Lorenz Räber, MD PhD(@RaberLorenz) 's Twitter Profile Photo

Only disappointingly little legacy effect following overweight medication cessation. (tirzepatide) How to predict longterm adherence to an expensive injectable? Overweight is a disease, not just bad habit. European Society of Cardiology SwissCardio

account_circle
PCRonline 🫀(@PCRonline) 's Twitter Profile Photo

Stent failure management:

Discover the optimal use of intracoronary ⭕️ imaging and learn more about the differential role of IVUS and OCT imaging in stent failure in this session replay 📺

Lorenz Räber, MD PhD Shereen AlShaikh Salvatore Brugaletta

pcronline.com/Cases-resource…

Stent failure management: Discover the optimal use of intracoronary ⭕️ imaging and learn more about the differential role of IVUS and OCT imaging in stent failure in this session replay 📺 @RaberLorenz @DrShereen_ @sbrugaletta pcronline.com/Cases-resource… #CardioTwitter
account_circle
Lorenz Räber, MD PhD(@RaberLorenz) 's Twitter Profile Photo

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension is very efficacious treatment option. Read the just released consensus statement of the ESC working group on pulmonary circulation&right ventricular function academic.oup.com/eurheartj/arti…

account_circle
MedscapeLIVE(@MedscapeLIVE) 's Twitter Profile Photo

Join experts Ph.Gabriel Steg , Dr. Deepak L. Bhatt, Lorenz Räber, MD PhD, Lale Tokgozoglu and learn the latest data 📊on lipid-lowering strategies in the post-ACS period
📅 26 August, 2023
📍Amsterdam,The Netherlands
🔗 esc365.escardio.org/ESC-Congress/s…

Join experts @gabrielsteg , @DLBHATTMD, @RaberLorenz, @LaleTokgozoglu and learn the latest data 📊on lipid-lowering strategies in the post-ACS period 📅 26 August, 2023 📍Amsterdam,The Netherlands 🔗 esc365.escardio.org/ESC-Congress/s… #cardiology #ESCcongress
account_circle
Faculty of Medicine, University of Bern(@MedFacultyUniBE) 's Twitter Profile Photo

Two Investigator Initiated Clinical Trial Grants from Schweizerischer Nationalfonds (SNF) for the Medical Faculty of Universität Bern. 🥂Congratulations to Reto Auer, Lorenz Räber, MD PhD, and David Seiffge for this big success. Here is a summary of their projects addressing important unmet needs: medizin.unibe.ch/research/index…

Two Investigator Initiated Clinical Trial Grants from @snf_ch for the Medical Faculty of @unibern. 🥂Congratulations to @retoauer, @RaberLorenz, and @DavidSeiffge for this big success. Here is a summary of their projects addressing important unmet needs: medizin.unibe.ch/research/index…
account_circle
Davide Capodanno(@DFCapodanno) 's Twitter Profile Photo

In PACMAN-AMI, the PCSK9i alirocumab led to significant regression of non-obstructive lesions at 1 year compared to placebo on top of rosuvastatin. New research shows that this effect did not translate into significant improvement in coronary physiology. eurointervention.pcronline.com/article/impact…

In PACMAN-AMI, the PCSK9i alirocumab led to significant regression of non-obstructive lesions at 1 year compared to placebo on top of rosuvastatin. New research shows that this effect did not translate into significant improvement in coronary physiology. eurointervention.pcronline.com/article/impact…
account_circle
Thomas Meinel(@TotoMynell) 's Twitter Profile Photo

Very nice session on breakthrough stroke despite anticoagulation at
This very common clinical problem needs our attention in clinics and research🧠🫀❤️💊
Sashi Perera, MD Edip Gurol Luciano Sposato 🇦🇷🇨🇦 David Seiffge Alex Polymeris Lorenz Räber, MD PhD

Very nice session on breakthrough stroke despite anticoagulation at #ESOC2023 This very common clinical problem needs our attention in clinics and research🧠🫀❤️💊 @PereraKanjana @guroledip @SposatoL @DavidSeiffge Alex Polymeris @RaberLorenz
account_circle